This Medudy course is a video tutorial for physicians on the topic of “First-line treatment of MSI-H/dMMR metastatic colorectal cancer: IO monotherapy or IO combination therapy—a case-based treatment decision.”
Prof. Dr. Dirk Arnold, Director of the Asklepios Tumor Center Hamburg and the Department of Oncology, Hematology, Palliative Medicine, Rheumatology, and Pulmonology at the Asklepios Clinic Altona, uses a specific patient case in this video to explain the current evidence-based first-line therapy for unresectable metastatic colorectal cancer with mismatch repair deficiency or high-grade microsatellite instability.
The focus is on comparing PD-1 monotherapy with combination therapy involving PD-1 and CTLA-4 blockade. The key study data for both strategies will be discussed—the KEYNOTE-177 study on pembrolizumab, including 5-year long-term data, as well as the CheckMate 8HW study on nivolumab plus ipilimumab, including current ESMO data from the direct first-line comparison. In addition, factors for clinical decision-making in the tumor board—tumor burden, symptom burden, organ involvement, general condition, and tolerance to toxicity—as well as the role of chemotherapy and the interpretation of early radiological changes during immunotherapy will be discussed.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy team of doctors.
This course was made possible with the generous support of MSD.
By the end of this course, you will know:
- The guideline-based first-line strategy for MSI-H/dMMR mCRC
- the key data from KEYNOTE-177 and CheckMate 8HW
- the factors to consider when deciding between IO monotherapy and an IO combination regimen
- The role of chemotherapy and managing early progression during immunotherapy
